TABLE 3 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
Year: 2024
Type: other
Abstract: Overall response rate for all participants receiving at least one cycle of treatment and for all patients evaluable by imaging
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4392166726
